

Work instructions

Title: Preparation of the annual GMP re-inspection programme				
Applies to: P-CI-MQC Section				
Status: PUBLIC		Document no.: WIN/INSP/2046		
Lead Author	Approver	Effective Date: 27-SEP-12		
Name: Claudio Facchini	Name: David Cockburn	Review Date: 27-SEP-15		
Signature: On file	Signature: On file	Supersedes:		
		N/A		
Date: 25-SEP-12	Date: 25-SEP-12	TrackWise record no.: 3402		

1. Changes since last revision

New WIN.

2. Records

Electronic copies of the documents prepared are stored in DREAM under Cabinets/04. Inspections/4. GMP/Planning and reporting/GMP inspections coordination.

Emails circulated for the preparation and finalisation of the programme are copied in the GMPINS mailbox, which can be found in Outlook under Public Folders / All Public Folders / Compliance and Inspection / MQC / GMPINS.

Documents needed for this WIN

• Template 1: Informing MAH about probable inspection request, saved in the X drive under: X:\Templates\Others\Compliance and Inspection\GMP\Inspection Coordination.

Related documents

- Compilation of Community procedures on inspections and exchange of information: EMA Public website > Home > Regulatory > Human medicines/Veterinary medicines > Inspections > GMP/GDP compliance > Community procedures.
- SOP/EMA/0101 Conducting checks for conflicts of interest of Agency employees assigned duties relating to medicinal products for human or veterinary use.
- SOP/INSP/2048 Co-ordination of GMP/GDP inspections.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8416 **E-mail** info@ema.europa.eu **Website** www.ema.europa.eu



An agency of the European Union

© European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged.

• WIN/INSP/2047 Inspection of quality control facilities located in 3rd countries.

3. Instructions

Abbreviations

AS = Active Substance.

- CAP = Centrally Authorised Product.
- CxMP = Committee for Medicinal Product for Human/Veterinary use.
- EEA = European Economic Area.
- EU = European Union.
- GDP = Good Distribution Practice.
- GMP = Good Manufacturing Practice.
- MA = Marketing Authorisation.
- MAH = Marketing Authorisation Holder.
- NCA = National Competent Authority.

P-CI-MQC = Manufacturing and Quality Compliance section, Compliance and Inspection sector, Patient Health Protection unit.

This WIN provides instructions for the preparation of the annual Good Manufacturing Practice (GMP) re-inspection programme for the year X. Such programme will include all the sites located in third countries (excluding those where a valid GMP agreement for the dosage form and/or the activity in question is in place) and for which a GMP inspection will be requested by the CxMP in the year X. Inspections requested in the year X are expected to be completed within 12 months from the month they were adopted unless otherwise justified. Because of the requirement set in the Compilation of Community Procedures, a site is usually re-inspected with a frequency which does not exceed three years unless otherwise justified.¹. This means that, in principle, sites where inspections are to be carried out in the year X+1, have been last inspected in the year X-2. In order to identify the manufacturing sites to be inspected, the P-CI-MQC section maintain an Access-based database (in this WIN called GMP database) in which these sites are recorded, together with the inspections dates.

¹ For inspections of quality control facilities located in 3rd countries, the interval between inspections should be no longer than 5 years (see WIN/INSP/2047).

р	Action	Responsibility
	By October of year X-1, in order to comply with the requirements of the Compilation of Community Procedures on the re-inspections frequency and on request of the Administrator, prepare a query in the GMP database according to the following instructions:	Assistant
	 Select `Objects-Queries' in the 'GMP Edit: Database' window; 	
	 Select, copy and paste one of the existing queries called `Re- inspection Programme YYYY'; 	
	 Rename new query with current year and double-click to open it; 	
	 Click on the first icon and on the toolbar to change to 'Design View' (see screenshot): 	
	Photos Average De (at yes juent Query Juen Winder juen ■ ■ ■ @ @ @ ♡ X @ @ ∮ en @ • 1 % X # • 12 % X @ @ • 0).	
	Image: contract of the state of the stat	
	Image: Date: Cond-table	
	Ready #Start : # A A A A A A A A A A A A A A A A A A	
	 Modify the query by changing the 'Criteria' in the 'Date of inspection' field, to include the dates of inspections carried out between 1 January and 31 December of the year X-2 (e.g. for 	
	the 2013 programme, >#01/01/2011# And <#31/12/2011#);	

				,	1		\mathbf{N}	
Field:		Address	City, State	CountryID	/	Date of Inspection	Name of A	Applicatio
Table:	tblSites	tblSites	tblSites	tblSites		tblGMPInspections	tblApplica	tions
Total:	Group By	Group By	Group By	Group By		Max	Group By	
Sort:						Ascending		
Show:	✓	Image: A start and a start	Image: A start of the start	✓				✓
Criteria:						>#01/01/2011# And <	Vot Like "	PMF*
or:								
	•							

• In order to identify quality control facilities, run also a query for

Step	Action	Responsibility
	 years X-3 and X-4, as this would allow to identify quality control sites that are re-inspected within the longest allowed interval of 5 years; Click on the first icon on the toolbar to change to 	
	'Datasheet View';	
	Click on 'Save' in order to export the query.	
	These queries will allow to identify the sites inspected in the year X-2, X-3, or X-4.	
2.	The query will allow to obtain the following information for each site:	Assistant
	• Full address;	
	• Date of last inspection;	
	 Name and pharmaceutical form(s) of each centrally authorised product (CAP) for which one or more manufacturing activities are carried out at the site; 	
	Export the result of the query into an Excel spreadsheet:	
	• Click on `File';	
	Select `Export';	
	• Choose location where the file will be saved (e.g. desktop);	
	• Save as `Microsoft Excel 97-2000' format.	
3.	Add to the spreadsheet the following information for each site:	Administrator
	 For each combination CAP/pharmaceutical form, the location of the batch release site; 	
	• For each CAP, whether it is a human/veterinary product;	
	 For each combination CAP/pharmaceutical form, the list of activities carried out at the site; 	
	 Supervisory authority based on the country where the batch release site is located; 	
	 Proposed lead inspectorate chosen among the supervisory authorities; 	
	 Proposed supporting inspectorate chosen among the supervisory authorities; 	
	 Proposed reporting deadline (12 months from the month of adoption unless otherwise justified). 	
	If necessary, remove the following information from the spreadsheet:	

Sites located in third countries with a valid GMP agreement for the dosage form and/or the activity in question; Sites where manufacture of non-sterile active substances for chemical products is carried out; Sites where manufacture of AS intermediate for chemical products is carried out; Sites where quality control for non-sterile active substances for chemical products is carried out. the list: Sites which manufacture sterile active substances for chemical products; Sites which manufacture active substances for biological products;	
chemical products is carried out; Sites where manufacture of AS intermediate for chemical products is carried out; Sites where quality control for non-sterile active substances for chemical products is carried out. The list: Sites which manufacture sterile active substances for chemical products; Sites which manufacture active substances for biological	
broducts is carried out; Sites where quality control for non-sterile active substances for chemical products is carried out. (a) in the list: Sites which manufacture sterile active substances for chemical products; Sites which manufacture active substances for biological	
chemical products is carried out. • in the list: Sites which manufacture sterile active substances for chemical products; Sites which manufacture active substances for biological	
Sites which manufacture sterile active substances for chemical products; Sites which manufacture active substances for biological	
products; Sites which manufacture active substances for biological	
Sites where quality control of sterile active substances for chemical products is carried out. Their inspection will be subject to the instructions contained in WIN/INSP/2047.	
ne end of November of year X-1 send the spreadsheet with the re-inspection programme to the GMP contact persons of the onal Competent Authorities (NCAs) in the EU/EEA Member es, asking to provide feedback in relation to:	Administrator
nspection team;	
Sites recently inspected as part of their national inspection programmes;	
Plan to inspect the sites as part of their national inspection programmes.	
list of contact persons can be found on the EMA intranet > ness applications > Eudra Common Directory > Contacts >	
ips (Official and Custom).	
	ist of contact persons can be found on the EMA intranet > ness applications > Eudra Common Directory > Contacts >

Step	Action	Responsibility
	Eudra Common Directory (ECD-2) - Windows Internet Explorer	
	Solution that the second secon	
	File Edit View Favorites Tools Help	
	👷 Favorites 🛛 🚖 🌆 Free Hotmail 🦉 Sign In 🖾 (0 unread) Yahoo! 🖻 Web Slice Gallery 🚽	
	🔠 • 🏉 Eudra Common × 🔛 2012	
	Welcome	
	ECD Manager (Rele	
	Tuesday, December	
	Contacts EMEA Internal Directory	1
	Log in ECD Manager	
	Vsername : Group Name : gmp*	
	Log In	
	ECD Resources 9 Result(s)	
	S Contacts	
	Organisations Group Name Short Name Image: Comparise of the state of	
	Search GMP/GDP Subgroup on Heparin GMP/GDP Heparin	
	GMP Annex 2 Drafting group Annex 2 GMP Compliance Group GMP Compliance G	
	GMP Inspections Planning - Human GMP Inspections Planning - Veterinary	
	G M P Request - H Good Manufacturing and Distribution Practice Inspectors Working Group GMP / GDP	
	Good Manufacturing and Distribution Practice Inspectors Working Group - Observers GMP / GDP - Observers	
	 relevant Marketing Authorisation Holder (MAH) informing that the site where the product is manufactured/packaged/tested etc. is going to be inspected using template 1. The email is to be sent by the end of December of year X-1 for the inspections to be requested between January and June of year X; by the end of May of year X, for the inspections to be requested between July and December of year X. Ask to provide the following information: Whether the site has had an inspection in the last two years; 	
	• Whether the site will be withdrawn from the marketing authorisation (MA) in the next six months.	
	Use the information collected in step 6 to finalise the spreadsheet by deleting sites or products which are not due to be inspected.	Administrator
	Assign an inspection co-ordinator to each site. This is done by checking in Siamed II who is the GMP inspection co-ordinator for most of the products related to the site. Appointment of the inspection co-ordinator is agreed with the Section Head who is responsible for the implementation of the SOP/EMA/0101.	Administrator
۶.	On an on-going basis, add to the scope of a site's inspection, those products (either new or existing) for which a new application (or a line extension/variation) shows that the site will be included in the	Assistant

Step	Action	Responsibility
	Continue with step 4 of SOP/INSP/2048.	